Compare Freshworks Inc (FRSH) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Mesoblast Limited — how do they compare? Freshworks Inc trades at $13.92 (market cap $3.56B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Freshworks Inc is far larger — about 2× Mesoblast Limited's market cap, and Freshworks Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Freshworks Inc for 39 Days and Mesoblast Limited for 15 Days on average.
| FRSH | MESO | |
|---|---|---|
Market Cap | $3.56B | $1.75B |
Volume | 9,066,454 | 239,027 |
Sector | Technology | Health |
52-Week High | $13.92 | $20.96 |
52-Week Low | $6.88 | $13.19 |
Typical Hold Time | 39 Days | 15 Days |
Enterprise Value | $2.93B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $13.92, up 2.35% today, with strong technical momentum and bullish moving averages. The company achieved its first GAAP profitability in Q2 2026, beating earnings expectations with $0.17 EPS versus $0.13 expected. Revenue growth remains robust at 16% year-over-year, while valuation metrics show a P/E of 21.63 and P/S of 4.28. Recent developments include FedRAMP certification progress and leadership appointments.
The outlook appears positive with analyst consensus at $14.60 price target and 50% buy ratings. Key opportunities include AI monetization and enterprise growth, while risks involve competitive SaaS market pressure and the need to sustain recent profitability gains amid ongoing investments.
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
